ecancer

Using PDL1 and other biomarkers in patient selection for immunology: Q & A

Dr O'Brien and Prof McVie

5 Oct 2016

We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Prof Gordon McVie - King's College London, London, UK

5 Oct 2016

Imaging and novel PET tracers: Q & A

Dr Giulia Veronesi and Prof Tony Ng

5 Oct 2016

Current standards of care in advanced NSCLC

Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada

5 Oct 2016

Imaging and novel PET tracers: The future

Prof Tony Ng - King's College London, London, UK

5 Oct 2016

Radiotherapy in lung cancer: Future directions

Dr David Landau - Guy's and St Thomas' NHS Trust, London, UK

5 Oct 2016

Radiotherapy - what's new? Q & A

Dr David Landau and Prof Corinne Favire-Finn

5 Oct 2016

Imaging and novel PET tracers: State of the art

Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy

5 Oct 2016

Radiotherapy in lung cancer: Current state of the art

Prof Corinne Faivre-Finn - Christie NHS Foundation Trust, Manchester, UK

5 Oct 2016

Metabolomics: Reversing drug resistance

Dr Olivier Pardo - Imperial College London, London, UK

14 Sep 2016

Tumour heterogeneity and the impact on patient care

Dr Nicholas McGranahan - The Francis Crick Institute, London, UK

14 Sep 2016

Developing new models in SCLC

Prof Caroline Dive - Cancer Research UK Manchester Institute, Manchester, UK

14 Sep 2016

More from ecancer